Immune Checkpoint Inhibitors Clinical Trials

Immune Checkpoint Inhibitors Overview

Oncology market, for decades, has been pillared on three areas: Surgery, Radiation Therapy and Chemotherapy. Immuno-oncology, especially immune checkpoint inhibitors, has recently gained traction from several stakeholders. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. The drug is currently being mirrored by various other drugs such as Opdivo, Keytruda, Empliciti and Tecentriq in clinical development.

The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Most common forms of partnerships include clinical trial collaborations, product licensing agreements, acquisitions and research collaborations.

In addition to the marketed drugs, we expect a number of drugs currently in advanced stages of development to achieve blockbuster status in the near future. The anticipated success of immune checkpoint inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Scope of the Report

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of immune checkpoint inhibitors.We have identified a number of immune checkpoint inhibitors and clinical trials that are either being conducted or planned to be conducted for each of these drugs. 

For each specific product, we have provided the following information:

• Primary Drug
• Highest Phase of Development
• Manufacturer / Licensee
• Target Receptor
• Molecule Type
• Route of Administration

For each specific trial, we have provided the following information:

1. Indication
2. Therapeutic Area
3. Type of Cancer
4. Sponsor/Collaborator
5. Trial Title
6. Trial Objective
7. Trial Phase
8. Trial Status
9. Start Date
10. End Date
11. Enrolment
12. Age Group
13. Age Range
14. Gender
15. Inclusion Criteria
16. Exclusion Criteria
17. Study Type
18. Study Design
19. Primary Endpoints
20. Secondary Endpoints
21. Other Endpoints
22. Treatment Arm(s)
23. Location(s)
24. Primary Trial Identifier
25. Other Identifiers
26. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

Drivers and Restraints of the specific drug classes (CTLA-4 inhibitors, PD-1 / PDL-1 inhibitors and novel immune checkpoint inhibitors), wherein we have presented our opinion on the drivers and challenges associated with each of the drug class type.

Sales forecast of the immune checkpoint inhibitors market over the course of next ten years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.